Argus
•
Oct 28, 2026
XNCR: Rating increased to a HOLD
Summary
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Regeneron Pharmaceuticals, Inc.
Oct 30, 2026
•
REGN
Analyst Report: Bristol-Myers Squibb Company
Oct 30, 2026
•
BMY
Analyst Report: Merck & Co., Inc.
Oct 29, 2026
•
MRK
Analyst Report: Biogen Inc.
Oct 29, 2026
•
BIIB
Analyst Report: Biogen Inc
Oct 29, 2026
•
BIIB
